According to the head of the agency Veronika Skvortsova, during the research, scientists confirmed that Leitragin "is able to prevent or mitigate a cytokine storm - a massive release of pro-inflammatory substances that leads to the development of severe respiratory and general systemic disorders in the patient."

The most effective way to use the new dosage form is inhalation, the FMBA stressed.

“Rospatent separately notes that Leitragin is a purely domestic drug, it itself, like all components, can be completely produced in Russia,” the message says.

Earlier, Rospotrebnadzor said that the Vector Center, when developing the EpiVacCorona vaccine, takes into account all the requirements and regulatory recommendations provided for by Russian legislation.